Skip to main content

Advertisement

SpringerLink
Log in

METTL3 Mediated MALAT1 m6A Modification Promotes Proliferation and Metastasis in Osteosarcoma Cells

  • Original Paper
  • Published:
Molecular Biotechnology Aims and scope Submit manuscript

Abstract

Background

As one of the most ubiquitous types of posttranscriptional modification, N6-methyladenosine (m6A) is extensively implicated in almost all types of cancers, including osteosarcoma. Our previous research partially uncovered the role of Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1) in osteosarcoma. However, the relationships between methyltransferase-like 3 (METTL3) and noncoding RNAs modified by METTL3, especially MALAT1, in osteosarcoma remain obscure.

Methods

The expression of METTL3 in osteosarcoma was evaluated by online bioinformatics analysis, immunohistochemical (IHC) staining, western blotting (WB), and reverse transcription–quantitative PCR (RT‒qPCR). Cell Counting Kit 8 (CCK-8) and Transwell assays were used to evaluate the cell proliferation and invasion abilities. The expression of MALAT1 in osteosarcoma was evaluated by online bioinformatics analysis and RT‒qPCR analysis. m6A methylated RNA immunoprecipitation-qPCR (MeRIP-qPCR) was used to detect m6A modification changes in MALAT1. An actinomycin D assay was used to study changes in the stability of MALAT1.

Results

METTL3 was upregulated in osteosarcoma tissues and cell lines. Functionally, METTL3 promoted the proliferation and migration of osteosarcoma cells. Moreover, a clear positive correlation was found between METTL3 and MALAT1 expression, and MALAT1 was upregulated in osteosarcoma tissues and cells. Mechanistically, the presence of m6A modification sites in MALAT1 and METTL3-mediated m6A modification increased the stability of MALAT1 in osteosarcoma cells and promoted their proliferation and migration.

Conclusion

In this study, it was concluded that in osteosarcoma cells, METTL3, acting as an oncogene, promoted m6A modification of MALAT1, increased the stability of MALAT, and enhanced MALAT1-mediated oncogenic function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data Availability

All the data involved in this study are listed.

References

  1. Moore, D. D., & Luu, H. H. (2014). Osteosarcoma Cancer Treat Res, 162: 65–92.

    Article  PubMed  Google Scholar 

  2. Simpson, E., & Brown, H. L. (2018). Understanding osteosarcomas. Jaapa, 31(8), 15–19.

    Article  PubMed  Google Scholar 

  3. Meng, Y., et al. (2021). Circular RNA circNRIP1 plays oncogenic roles in the progression of osteosarcoma. Mammalian Genome, 32(6), 448–456.

    Article  CAS  PubMed  Google Scholar 

  4. Ianniello, Z., Paiardini, A., & Fatica, A. (2019). N(6)-Methyladenosine (m(6)A): A Promising New Molecular Target in Acute Myeloid Leukemia. Frontiers in Oncology, 9, 251.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Karthiya, R., & Khandelia, P. (2020). m6A RNA methylation: Ramifications for gene expression and Human Health. Molecular Biotechnology, 62(10), 467–484.

    Article  CAS  PubMed  Google Scholar 

  6. Meyer, K. D., et al. (2012). Comprehensive analysis of mRNA methylation reveals enrichment in 3’ UTRs and near stop codons. Cell, 149(7), 1635–1646.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bokar, J. A., et al. (1997). Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase. Rna, 3(11), 1233–1247.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Zeng, C., & Huang, W. (2020). Roles of METTL3 in cancer: Mechanisms and therapeutic targeting. 13(1): p. 117.

  9. Zhang, W., et al. (2020). Multifaceted functions and Novel Insight into the Regulatory Role of RNA N(6)-Methyladenosine modification in Musculoskeletal disorders. Front Cell Dev Biol, 8, 870.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Ling, Z., Chen, L., & Zhao, J. (2020). m6A-dependent up-regulation of DRG1 by METTL3 and ELAVL1 promotes growth, migration, and colony formation in osteosarcoma Biosci Rep, 40(4).

  11. Wang, J., et al. (2022). m6A-dependent upregulation of TRAF6 by METTL3 is associated with metastatic osteosarcoma. J Bone Oncol, 32, 100411.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Wei, K., et al. (2022). Methylation recognition protein YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) regulates the proliferation, migration and invasion of osteosarcoma by regulating m6A level of CCR4-NOT transcription complex subunit 7 (CNOT7). Bioengineered, 13(3), 5236–5250.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Zhou, C., et al. (2020). N6-Methyladenosine modification of the TRIM7 positively regulates tumorigenesis and chemoresistance in osteosarcoma through ubiquitination of BRMS1. EBioMedicine, 59, 102955.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Zhou, X., et al. (2021). METTL3 contributes to Osteosarcoma Progression by increasing DANCR mRNA Stability via m6A modification. Front Cell Dev Biol, 9, 784719.

    Article  PubMed  Google Scholar 

  15. Farzaneh, M., et al. (2023). LncRNA MALAT1-related signaling pathways in osteosarcoma. Clinical and Translational Oncology, 25(1), 21–32.

    Article  CAS  PubMed  Google Scholar 

  16. Malakoti, F., et al. (2021). Multiple function of lncRNA MALAT1 in cancer occurrence and progression. Chem Biol Drug Des.

  17. Wang, Y., et al. (2017). Long non-coding RNA MALAT1 for promoting Metastasis and proliferation by acting as a ceRNA of mir-144-3p in osteosarcoma cells. Oncotarget, 8(35), 59417–59434.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Tao, L., et al. (2021). FTO modifies the m6A level of MALAT and promotes Bladder cancer progression. Oral Diseases, 11(2), e310.

    CAS  Google Scholar 

  19. Li, J., Momen-Heravi, F., & Wu, X. (2023). Mechanism of METTL14 and m6A modification of lncRNA MALAT1 in the proliferation of oral squamous cell carcinoma cells. Clin Transl Med, 29(5), 2012–2026.

    Google Scholar 

  20. Jiang, R., et al. (2022). METTL3 stabilizes HDAC5 mRNA in an m(6)A-dependent manner to facilitate malignant proliferation of osteosarcoma cells. Cell Death Discov, 8(1), 179.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Zeng, K., et al. (2018). CircHIPK3 promotes Colorectal cancer growth and Metastasis by sponging miR-7. Cell Death and Disease, 9(4), 417.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Chen, S., et al. (2019). TCM therapies combined with chemotherapy for preventing recurrence and Metastasis in postoperative II to IIIA NSCLC: A protocol for a systematic review and meta-analysis. Medicine (Baltimore), 98(9), e14724.

    Article  PubMed  Google Scholar 

  23. Wang, Y., et al. (2018). Long noncoding RNA DANCR, working as a competitive endogenous RNA, promotes ROCK1-mediated proliferation and Metastasis via decoying of mir-335-5p and miR-1972 in osteosarcoma. Molecular Cancer, 17(1), 89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Wang, Y., et al. (2017). Long non-coding RNA TUG1 promotes migration and invasion by acting as a ceRNA of mir-335-5p in osteosarcoma cells. Cancer Science, 108(5), 859–867.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Zhou, Y., et al. (2023). Silencing of IRF8 mediated by m6A modification promotes the progression of T-Cell Acute Lymphoblastic Leukemia. Adv Sci (Weinh), 10(2), e2201724.

    Article  PubMed  Google Scholar 

  26. Ratnadiwakara, M., & Änkö, M. L. (2018). mRNA Stability Assay using transcription inhibition by actinomycin D in mouse pluripotent stem cells. Bio Protoc, 8(21), e3072.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Barrett, T., et al. (2013). NCBI GEO: Archive for functional genomics data sets–update. Nucleic Acids Research, 41(Database issue), D991–D995.

    CAS  PubMed  Google Scholar 

  28. Chandrashekar, D. S., et al. (2022). UALCAN: An update to the integrated cancer data analysis platform. Neoplasia (New York, N.Y.), 25, 18–27.

    Article  CAS  PubMed  Google Scholar 

  29. Chandrashekar, D. S., et al. (2017). UALCAN: A portal for facilitating Tumor Subgroup Gene expression and survival analyses. Neoplasia (New York, N.Y.), 19(8), 649–658.

    Article  CAS  PubMed  Google Scholar 

  30. Tang, Z., et al. (2019). GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Research, 47(W1), W556–w560.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Zhou, Y., et al. (2016). SRAMP: Prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features. Nucleic Acids Research, 44(10), e91.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Xuan, J. J., et al. (2018). RMBase v2.0: Deciphering the map of RNA modifications from epitranscriptome sequencing data. Nucleic Acids Research, 46(D1), D327–d334.

    Article  CAS  PubMed  Google Scholar 

  33. Roundtree, I. A., et al. (2017). Dynamic RNA modifications in Gene expression regulation. Cell, 169(7), 1187–1200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Liu, N., et al. (2015). N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature, 518(7540), 560–564.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Wang, X., et al. (2015). N(6)-methyladenosine modulates Messenger RNA translation efficiency. Cell, 161(6), 1388–1399.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Wang, X., et al. (2014). N6-methyladenosine-dependent regulation of messenger RNA stability. Nature, 505(7481), 117–120.

    Article  PubMed  Google Scholar 

  37. Alarcón, C. R., et al. (2015). N6-methyladenosine marks primary microRNAs for processing. Nature, 519(7544), 482–485.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Deng, X., et al. (2018). RNA N(6)-methyladenosine modification in cancers: Current status and perspectives. Cell Research, 28(5), 507–517.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Zhao, W., et al. (2020). Epigenetic regulation of m(6)a modifications in Human Cancer. Mol Ther Nucleic Acids, 19, 405–412.

    Article  CAS  PubMed  Google Scholar 

  40. Zeng, C., et al. (2020). Roles of METTL3 in cancer: Mechanisms and therapeutic targeting. Journal of Hematology & Oncology, 13(1), 117.

    Article  Google Scholar 

  41. Wu, Y., et al. (2022). The role of m6A methylation in osteosarcoma biological processes and its potential clinical value. Human Genomics, 16(1), 12.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Han, Y. (2019). CVm6A: A visualization and exploration database for m6As in cell lines. Cells, 8(2).

  43. Zhang, Z., et al. (2021). N6-Methyladenosine-sculpted Regulatory Landscape of noncoding RNA. Frontiers in Oncology, 11, 743990.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Chen, L., et al. (2022). METTL3-mediated m6A modification stabilizes TERRA and maintains telomere stability. Nucleic Acids Research, 50(20), 11619–11634.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Ni, W., et al. (2019). Long noncoding RNA GAS5 inhibits progression of Colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m(6)a reader YTHDF3. Molecular Cancer, 18(1), 143.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Zhang, H., et al. (2022). m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression. Cell Death and Disease, 13(7), 657.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

None.

Funding

None.

Author information

Authors and Affiliations

  1. Fourth Department of Orthopedic Surgery, Central Hospital Affiliated to Shenyang Medical College, No. 5 South Seven West Road, Tiexi, Shenyang, 110024, Liaoning, P.R. China

    Yuanzhuang Zhang, Yeqiu Xu, Guanzhen Qiu, Yinzhou Luo, Yuxin Bao, Tao Wang & Yong Wang

  2. Department of Cardiology, Shenyang Fourth People’s Hospital, China Medical University, Shenyang, 110031, Liaoning, P.R. China

    Jie Lu

Authors
  1. Yuanzhuang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yeqiu Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guanzhen Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yinzhou Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuxin Bao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jie Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YZ, YX and GQ were responsible for the performance of the experiments; YZ was responsible for the manuscript writing, figure completion and revision of the research. YL, YB, JL and TW were responsible for statistical analysis of the data. YW was mainly responsible for the scientific research and study design.

Corresponding authors

Correspondence to Tao Wang or Yong Wang.

Ethics declarations

Patient Consent for Publication

Not applicable.

Ethical Approval and Consent to Participate

The Medical Ethics Committee of Central Hospital Affiliated with Shenyang Medical College approved this study (approval number: 2019DEC12-4), and all patients provided written informed consent.

Competing Interests

All authors state the absence of competing interests in the research and writing of the article.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Supplementary Material 2

Supplementary Material 3

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Y., Xu, Y., Qiu, G. et al. METTL3 Mediated MALAT1 m6A Modification Promotes Proliferation and Metastasis in Osteosarcoma Cells. Mol Biotechnol (2023). https://doi.org/10.1007/s12033-023-00953-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12033-023-00953-2

Keywords

Search

Navigation